Jun Tang

deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium.

Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France.

Part of Pfizer Inc., Pfizer Japan, Inc. is a research and Japanese development pharmaceutical company founded in 1953. The company is based in Tokyo, Japan. The company's focus is on breakthroughs that greatly change patients' lives, contributing to the improvement of patients' health and life expectancy.

Part of Bristol Myers Squibb Co., Bristol-Myers Squibb KK develops, manufactures and markets biopharmaceutical products. The company is based in Shinjuku-ku, Japan.

s.maX Co., Ltd. provides health care services. The private company is based in Tokyo, Japan.

Part of Sun Pharmaceutical Industries Ltd., Sun Pharma Japan Ltd. is a specialty generic pharmaceutical company based in Tokyo, Japan. The Japanese company remains committed to creating long term value for its shareholders and focuses on performance and producing consistent returns. The Ministry of Corporate Affairs (MCA) notified the IEPF (Uploading of Information Regarding Unpaid and Unclaimed Amounts Lying with Companies) Rules, 2012 (IEPF Rules), which is applicable to the corporation. Information and announcements about this can be found on the company's website. The company has revenues of over US$ 4.5 billion and completed the acquisition of Ranbaxy Laboratories Limited, an international pharmaceutical company, in 2015.